Company intelligence / Profile preview

Bio-Pharm Solutions

Suwon-si, Gyeonggi-do, South Koreab-psol.com ↗

Ownership: Private
Development stage: Other

Overview

Bio‑Pharm Solutions has advanced its lead program for infantile spasms into Phase 2 clinical trials in the US. Its status epilepticus program is in Phase 1. The company has expanded its pipeline to include programs for Alzheimer’s and Parkinson’s diseases, with preclinical work ongoing. The company received IND approval from the US FDA for its first epilepsy drug within five years of founding.

Therapeutic areas: Neurology
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

10 assets

JBPOS0101

9 more assets in the full pipeline.

Request access →

Partnerships

Joint research with National Institutes of Health (NIH)cooperation with global consulting networksinterest from global pharmaceutical companies

Beyond the preview

Go deeper on Bio-Pharm Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio-Pharm Solutions.

Explore the full profile